Pradeep Sharma, M.D. Anderson Chair Professor and department chair at the University of Houston, was named to the National Academy of Engineering. Photo via uh.edu

A national organization has named its latest cohort of new members — which includes Elon Musk — and five Houston-area innovators have also made the cut.

The National Academy of Engineering elected 111 new members and 22 international members, bringing the total U.S. membership to 2,388 and the number of international members to 310. The appointment is among the highest professional distinctions in an engineer's career. Each member has been found to have made significant contributions to "engineering research, practice, or education, including, where appropriate, significant contributions to the engineering literature," according to a news release.

The newly elected class will be formally inducted during the NAE's annual meeting on Oct. 2. The five Houston-area appointees and what they are being recognized for are:

  • Richard G. Baraniuk, C. Sidney Burrus Professor, Department of Electrical and Computer Engineering, Rice University. For the development and broad dissemination of open educational resources and for foundational contributions to compressive sensing.
  • Donald Nathan Meehan, president, CMG Petroleum Consulting Ltd.. For technical and business innovation in the application of horizontal well technology for oil and gas production.
  • Pradeep Sharma, M.D. Anderson Chair Professor and department chair, Department of Mechanical Engineering, University of Houston. For establishing the field of flexoelectricity, leading to the creation of novel materials and devices and insights in biophysical phenomena.
  • Leon Thomsen, chief scientist, Delta Geophysics Inc. For contributions to seismic anisotropy concepts that produced major advances in subsurface analysis.
  • David West, corporate fellow, Corporate Research and Innovation, Saudi Basic Industries Corp. For solutions to problems with technological, commercial, and societal impacts while advancing chemical sciences by applying reaction engineering fundamentals.

In a news release from UH, Sharma says it's the highest honor he could achieve as an engineer. The NAE recognized Sharma's work within flexoelectricity, a relatively understudied, exotic phenomenon that has the potential to provide similar functionality as piezoelectrics.

“Nature has provided us very few piezoelectric materials even though their applications in energy harvesting and in making sensors is very important. What we did was use theory to design materials that perform like piezoelectric ones, so that they can create electricity,” says Sharma in the release.

Sharma has worked at UH since 2004, and previously conducted research at General Electric for three years.

“The recognition of Professor Sharma by the National Academy of Engineering highlights a career full of outstanding research that has contributed to the understanding of engineering and helped uncover solutions for some of the world’s most significant problems,” says Paula Myrick Short, UH senior vice president for academic affairs and provost, in the release.

Over at Rice, Baraniuk's engineering career includes computational signal processing, most recently as it relates to machine learning. He's best known for spearheading the creation of Connexions, one of the first open-source education initiatives, and its successor, OpenStax, which publishes high-quality, peer-reviewed textbooks that are free to download.

“It’s auspicious timing that the NAE citation mentioned open education, because the seventh of February was the 10th anniversary of OpenStax publishing its first free and open textbook,” he says in a release from Rice. “It’s neat to have this happen in the same week, and worth pointing out that if ever there was a team effort, it was Connexions and OpenStax.”

Baraniuk has been at Rice since 1992, has three degrees in electrical and computer engineering.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston space company lands latest NASA deal to advance lunar logistics

To The Moon

Houston-based space exploration, infrastructure, and services company Intuitive Machines has secured about $2.5 million from NASA to study challenges related to carrying cargo on the company’s lunar lander and hauling cargo on the moon. The lander will be used for NASA’s Artemis missions to the moon and eventually to Mars.

“Intuitive Machines has been methodically working on executing lunar delivery, data transmission, and infrastructure service missions, making us uniquely positioned to provide strategies and concepts that may shape lunar logistics and mobility solutions for the Artemis generation,” Intuitive Machines CEO Steve Altemus says in a news release.

“We look forward to bringing our proven expertise together to deliver innovative solutions that establish capabilities on the [moon] and place deeper exploration within reach.”

Intuitive Machines will soon launch its lunar lander on a SpaceX Falcon 9 rocket to deliver NASA technology and science projects, along with commercial payloads, to the moon’s Mons Mouton plateau. Lift-off will happen at NASA’s Kennedy Space Center in Florida within a launch window that starts in late February. It’ll be the lander’s second trip to the moon.

In September, Intuitive Machines landed a deal with NASA that could be worth more than $4.8 billion.

Under the contract, Intuitive Machines will supply communication and navigation services for missions in the “near space” region, which extends from the earth’s surface to beyond the moon.

The five-year deal includes an option to add five years to the contract. The initial round of NASA funding runs through September 2029.

Play it back: Houston home tech startup begins 2025 with fresh funding

HOUSTON INNOVATORS PODCAST EPISODE 272

One of the dozen or so Houston startups kicking of the new year with fresh funding is SmartAC.com, a company that's designed a platform that enables contractors in the HVAC and plumbing industries to monitor, manage, and optimize their maintenance memberships through advanced sensors, AI-driven diagnostics, and proactive alerts.

Last month, the SmartAC.com raised a follow-on round with support from local investor Mercury to continue growth and expansion of the product, which has evolved on many ways since the company launched in 2020, emerging from stealth with $10 million raised in a series A. In a May 2023 interview for the Houston Innovators Podcast, Founder and CEO Josh Teekell explained how he embraced the power of a pivot.

The company's sensors can monitor all aspects of air conditioning units and report back any issues, meaning homeowners have quicker and less costly repairs. While SmartAC.com started with providing the service and tech to homeowners directly, Teekell says he's had a greater interest in working with plumbers and HVAC companies who then deploy the technology to their customers.

"It became quite evident that homeowners don't care about air conditioning really at all until their system breaks," Teekell says on the show. "The technology is really built around giving those contractors as another way to gain a customer relationship and keep it."

Revisit the podcast episode below where Teekell talks about SmartAC.com's last raise.

SmartAC.com's previous round in 2023 — a $22 million series B — was used grow its team that goes out to deploy the technology and train the contractors on the platform.

"We've been very fortunate to get some of the biggest names in Houston on our cap table," Teekell says in the May 2023 conversation. "Since we're raising a bunch of money locally, everyone understands what a pain air conditioning can be."

Houston biotech company tests hard-to-fight cancer therapeutics

fighting cancer

A Houston-based, female-founded biotech company has developed a treatment that could prove to be an effective therapy for a rare blood cancer.

Cellenkos Therapeutics has completed promising Phase 1b testing of its Treg cell therapy, CK0804, in the fight against myelofibrosis. According to a news release from the Cellenkos team, the use of its cord-blood-derived therapeutics could signal a paradigm shift for the treatment of this hard-to-fight cancer.

Cellenkos was founded by MD Anderson Cancer Center physician and professor Simrit Parmar. Her research at the hospital displayed the ability of a unique subset of T cells’ capability to home in on a patient’s bone marrow, restoring immune balance, and potentially halting disease progression.

Myelofibrosis has long been treated primarily with JAK (Janus Kinase) inhibitors, medications that help to block inflammatory enzymes. They work by suppressing the immune response to the blood cancer, but don’t slow the progression of the malady. And they’re not effective for every patient.

“There is a significant need for new therapeutic options for patients living with myelofibrosis who have suboptimal responses to approved JAK inhibitors,” Parmar says. “We are greatly encouraged by the safety profile and early signs of efficacy observed in this patient cohort and look forward to continuing our evaluation of the clinical potential of CK0804 in our planned expansion cohort.”

The expansion cohort is currently enrolling patients with myelofibrosis. What exactly are sufferers dealing with? Myelofibrosis is a chronic disease that causes bone marrow to form scar tissue. This makes it difficult for the body to produce normal blood cells, leaving patients with fatigue, spleen enlargement and night sweats.

Myelofibrosis is rare, with just 16,000 to 18,500 people affected in the United States. But for patients who don’t respond well to JAKs, the prognosis could mean a shorter span than the six-year median survival rate outlined for the disease by Cleveland Clinic.

Helping myelofibrosis patients to thrive isn’t the only goal for Cellenkos right now.

The company seeks to aid people with rare conditions, particularly inflammatory and autoimmune disorders, with the use of CK0804, but also other candidates including one known as CK0801. The latter drug has shown promising efficacy in aplastic anemia, including transfusion independence in treated patients.

The company closed its $15 million series A round led by BVCF Management, based in Shanghai, in 2021. Read more here.